Hoya Corporation · TSE:7741
Hoya — Q2 FY2026 Earnings Presentation
26 slides from Hoya's earnings presentation, Oct 30, 2026
Slide 1: HOYA Corporation FY26 Q2 Earnings Presentation
HOYA Corporation FY26 Q2 Earnings Presentation October 30, 2026 © 2026 HOYA CORPORATION All Rights Reserved
Slide 2: FY26 Q2 Results
FY26 Q2 Results © 2026 HOYA CORPORATION All Rights Reserved
Slide 3: FY26 Q2 Overview
FY26 Q2 Overview • [Revenue] Information Technology drove consolidated revenue growth into double digits. • [Operating Profit] Higher Information Technology sales and improved Life Care margins drove strong profit growth. • Quarterly revenue and profit renewed record highs. Revenue Operating Profit
Slide 4: Life Care Business
Life Care Business • [Revenue] Stable Eye Health performance and positive FX translation supported revenue growth. • [Operating Profit] Margin improved on product mix and cost optimization, returning to the target range. Revenue (¥bn) Operating Profit/OPM 154.8 153.4 146.9 21.2% 19.4% 17.6% 29.9 32.
Slide 5: Eyeglass Lenses
Eyeglass Lenses • U.S. sales declined amid ongoing restructuring, resulting in broadly flat sales YoY. MiYOSMART and other value-added products continued to grow. Sales Growth +8% • MiYOSMART Gen 2 rollout progressed in China and other markets. (CC +1%) • Strengthening sales, production and service
Slide 6: Contact Lenses (eyecity)
Contact Lenses (eyecity) • Private-label and subscription growth improved retention, supporting stable sales. Sales Growth +1% • Revenue was broadly flat against a relatively high prior-year base. (CC +1%) • We will enhance convenience to strengthen our customer base and deliver stable growth. © 202
Slide 7: Endoscopes
Endoscopes • China’s imported endoscope market continued to shrink amid policies promoting domestic products. Sales Growth -10% • Sales remained weak in the U.S. amid intense competition. (CC -16%) • We are rebuilding sales and service operations and improving efficiency to restore performance. © 20
Slide 8: IOLs
IOLs • Sales continued to decline in China and were negatively impacted by reimbursement changes in Germany. Stable sales in Japan and Sales Growth other Asian markets supported overall growth. +5% • Trifocal and enhanced monofocal IOL sales continued to expand. (CC +1%) • We aim to restore growth i
Slide 9: Artificial Bone and Other
Artificial Bone and Other • Sales of endoscope disinfection washers and metal implants remained solid, while chromatography media, which continued to be affected by inventory adjustments, and laparoscopic surgical instruments declined. Sales Growth +2% • Metal implants contributed to sales growth, d
Slide 10: Information Technology Business
Information Technology Business • [Revenue] All product lines grew strongly, delivering over 20% growth for the second consecutive quarter. • [Operating Profit] The profit margin remained elevated, supported by continued growth in sales of value-added products. Revenue (¥bn) Operating Profit/OPM 106
Slide 11: LSI
LSI • Demand for advanced EUV blanks remained solid, supported by AI-related investment. Sales Growth • Sales of high-value-added EUV blanks, including low-defect and +20% phase-shift mask products, continued to expand. (CC +18%) • Advancing customer engagement and internal validation for 12- inch H
Slide 12: FPD
FPD • Revenue rose sharply on higher sales to a major Korean customer, despite temporary softness in the FPD photomask market. Sales Growth • Development demand remained solid for advanced displays, +21% particularly smartphones and IT OLED. (CC +13%) • We are advancing high-resolution, high-value-a
Slide 13: HDD Substrates
HDD Substrates • Strong data center investment further expanded nearline HDD demand, driving a sharp increase in 3.5-inch substrate volumes. Sales Growth • Glass adoption advanced through wider HAMR use and higher +32% platter counts in non-HAMR drives. (CC +23%) • As HDD makers raise demand forecas
Slide 14: Optical Solutions
Optical Solutions • Sales of products used in interchangeable lenses grew despite a softer camera market, driven by a focus on premium products. Sales Growth +14% • Strong CUPO polarization glass sales for optical transceivers drove growth amid expanding AI data center investment. (CC +7%) • We are
Slide 15: MiYOSMART Update
MiYOSMART Update © 2026 HOYA CORPORATION All Rights Reserved
Slide 16: The Global Myopia Landscape
The Global Myopia Landscape Around half of the world’s population is projected to be myopic by 2050. Myopia prevalence among children and adolescents reached 35.8% in the 2020–2023 estimate. Global myopia prevalence (all ages) Global prevalence in children and adolescents 49.8% 35.8% 24.3% 22.9% 200
Slide 17: Main Myopia Management Solutions
Main Myopia Management Solutions • There are four main types of myopia management solutions. • HOYA launched MiYOSMART, a myopia management (MM) spectacle lens, in 2018. Orthokeratology Low-dose Atropine MM Soft MM Spectacle Lenses Lenses Eye Drops Contact Lenses *Product approval status varies by c
Slide 18: How Does MiYOSMART Work?
How Does MiYOSMART Work? • Hundreds of lenslets are arranged around the clear central zone to create peripheral myopic defocus and help slow axial elongation. • A clinical trial conducted in Hong Kong confirmed a 62% reduction in axial elongation. How MiYOSMART Works Hong Kong Clinical Trial Results
Slide 19: Estimated Myopia Management Market Opportunity
Estimated Myopia Management Market Opportunity • The estimated market opportunity for myopia management (MM) solutions is $3.6 billion after affordability adjustment. The MM spectacle lens wholesale market is only $0.5 billion, leaving substantial room for growth. • The MM spectacle lens market is e
Slide 20: MiYOSMART Sales Trend
MiYOSMART Sales Trend • 21% CAGR since FY21; MiYOSMART now represents close to 10% of eyeglass lens sales. • China remains a major market, while Europe has recently become an increasingly important growth driver. Sales by Region Other APAC Europe China FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25 FY26E ©
Slide 21: Launch of Second-Generation MiYOSMART
Launch of Second-Generation MiYOSMART • MiYOSMART iQ, the second-generation product, was launched first in China in winter 2025, followed by other markets. • Compared with the first generation, the layout, power and coverage were changed to strengthen the intended myopic defocus signal. First genera
Slide 22: MiYOSMART iQ: 12-Month Clinical Trial Results
MiYOSMART iQ: 12-Month Clinical Trial Results In a 12-month clinical trial, children wearing MiYOSMART iQ showed no myopia progression on average. Average Myopia Progression (cSER, D) over the first 12 months 1-4 • More negative values indicate greater myopia 0.046 progression. • 12-month randomised
Slide 23: MiYOSMART iQ Global Rollout Schedule
MiYOSMART iQ Global Rollout Schedule • Planned expansion to 54 countries by the end of FY26 Q3, matching the first-generation MiYOSMART footprint. • In existing markets, we will leverage the clinical evidence to expand our customer base and outgrow the low-to- mid-teens market growth rate. Cumulativ
Slide 24: Forward-looking Statement
24 Forward-looking Statement HOYA may make comments and disclose information which include forward-looking statements with respect to HOYA’s plans and future performance. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements and are
Slide 25: Notes
25 Notes ✓ Accounting standard: IFRS ✓ The fiscal year ending March 2027 is referred to as “FY26” throughout this document. ✓ Figures less than 100 million yen are rounded. Accordingly, some discrepancies may occur among totals. Ratios are calculated using actual numbers. ✓ Operating profit is calcu
Slide 26: Innovating for a Better Tomorrow
Innovating for a Better Tomorrow